LRRK2 (Leucine-Rich Repeat Kinase 2) mutant dopamine neurons are induced pluripotent stem cell (iPSC)-derived neurons carrying pathogenic mutations in the LRRK2 gene, most commonly the G2019S gain-of-function mutation. These neurons serve as a critical disease model for studying the pathogenesis of late-onset sporadic Parkinson's disease (PD) and testing therapeutic interventions. [1]
| Property | Value | [2]
|----------|-------| [3]
| Category | Disease Model Neurons | [4]
| Location | Substantia nigra pars compacta (model) | [5]
| Cell Types | LRRK2 G2019S iPSC-derived dopamine neurons |
| Primary Neurotransmitter | Dopamine |
| Key Markers | TH (Tyrosine Hydroxylase), DAT (Dopamine Transporter), LRRK2, Phospho-Rab10 |
The LRRK2 gene encodes a large multidomain protein with serine/threonine kinase activity. Several pathogenic mutations cause familial and sporadic PD:
The G2019S mutation increases kinase activity by approximately 2-3 fold, leading to enhanced phosphorylation of LRRK2 substrates including Rab10, Rab8A, and Rab12.
LRRK2 mutant dopamine neurons exhibit several mitochondrial abnormalities:
LRRK2 G2019S iPSC-derived dopamine neurons provide a human cellular model that recapitulates key features of sporadic PD:
Several LRRK2 inhibitors are in clinical development:
LRRK2 mutant dopamine neurons enable:
These neurons help elucidate:
Cookson MR. LRRK2 pathways in Parkinson's disease. Nat Rev Neurosci. 2010. 2010. ↩︎
Alessi DR, Sammler E. LRRK2 kinase in Parkinson's disease. Brain. 2019. 2019. ↩︎
Brichta L, et al. Identification of neuronal vulnerabilities in Parkinson's disease using human iPSC models. Nat Neurosci. 2015. 2015. ↩︎
Singh A, et al. LRRK2 G2019S mutation induces mitochondrial dysfunction in iPSC-derived dopamine neurons. Stem Cell Reports. 2019. 2019. ↩︎
Boehme M, et al. LRRK2 kinase inhibition rescues deficits in dopaminergic neuron function in a LRRK2 transgenic mouse model. Sci Transl Med. 2021. 2021. ↩︎